+91-8668442535

Treatment-Resistant Depression (TRD) Treatment Market By Drug Class (Selective serotonin reuptake inhibitors, Monoamine Oxidase Inhibitors, Tricyclic Antidepressant Inhibitors, Anti-N-methyl-d-aspartate receptor, Others) By Distribution Channel (Hospital pharmacies, Retail Pharmacies, Online Pharmacies) - Growth, Future Prospects And Competitive Analysis, 2016 – 2028

What are the different treatment options for Treatment-Resistant Depression (TRD)?

Treatment-Resistant Depression is described as depression that does not react or improves after being treated with two different antidepressant classes. Furthermore, it is a difficult clinical problem that is utilised to define the elements that influence serious depression disorders. In addition, in the treatment of treatment-resistant depression, integrated therapeutic techniques such as changing antidepressants, optimising drugs, using a combination of antidepressants, and using physiological therapies are used. Electroconvulsive therapy, magnetic seizure therapy, deep brain stimulation, transcranial direct current stimulation, repetitive transcranial magnetic stimulation, and vagus nerve stimulation are among the somatic therapies employed. Depression is the most prevalent clinical condition associated with mental illnesses.

According to a WHO article named "Depression" released in September 2021, depression is a prevalent disorder globally, affecting an estimated 3.8% of the population, including 5.0% of adults and 5.7% of persons over 60 years. Depression affects around 280 million people globally. It can cause a person to suffer greatly and perform poorly at work, school, and in the family. In the worst-case situation, depression can lead to suicide. Every year, over 700,000 people commit suicide. TRD, on the other hand, has two therapy options: pharmacological and non-pharmacological therapies. Among the pharmacologic therapy options include switching, combination, and potentiation strategies among commonly used antidepressant medications.

TRD is treated with antidepressants such as selective serotonin reuptake inhibitors (SSRIs), non-selective monoamine oxidase inhibitors (MAOIs), a2-antagonists, Agomelatine, dual serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, irreversible, and Tianeptine. Non-pharmacological therapies include electroconvulsive therapy (ECT), vagus nerve stimulation (VNS), and repetitive transcranial magnetic stimulation (rTMS). Furthermore, interpersonal therapy are two additional psychotherapy approaches (IPT) and cognitive-behavioral therapy (CBT).

treatment-resistant-depression-market.img1

What is the Market Size of Treatment-Resistant Depression (TRD) Treatment in terms of value?

The global Treatment-Resistant Depression (TRD) Treatment Market is projected to increase at a significant CAGR of 3.50% in the coming years. In 2021, the global Treatment-Resistant Depression (TRD) Treatment market was valued at USD 1318.5 million and is projected to reach at the value of USD 1620.77 million by 2028. The demand for Treatment-Resistant Depression (TRD) Treatment is projected to increase substantially in the coming years and is presumed to generate revenue opportunities for the key industry players worth USD 302.27 million during the forecast period of 2022 and 2028. 

What is the key emerging drugs for Treatment-Resistant Depression (TRD) Treatment?

  • AXS-05: Axsome Therapeutics- AXS-05 is a new NMDA receptor antagonist with multimodal activity that is being studied orally. It is being developed to treat central nervous system (CNS) problems and has a proprietary formulation and dose of dextromethorphan (DM) and bupropion. Axsome Therapeutics' AXS-05 received Priority Review from the FDA (dextromethorphan-bupropion). The accelerated review framework reduces the review time from a standard 10-month period to just six months after the receipt of the New Drug Application (NDA).
  • VRAYLAR (Cariprazine): AbbVie- Cariprazine is an atypical antipsychotic that is taken once a day. It's a partial agonist for the central dopamine D3 and D2 receptors that preferentially binds to the D3 receptor. It also acts as a partial agonist on serotonin 5-HT1A receptors and as an antagonist on serotonin 5-HT2A receptors. Cariprazine functions as a partial agonist with a high binding affinity at dopamine D3, dopamine D2, and serotonin 5-HT1A receptors, according to pharmacodynamic investigations.

Interesting Facts about Treatment-Resistant Depression (TRD) Treatment Industry

  • The Treatment-resistant Depression (TRD) market is expected to change in the coming years as a result of increased awareness of the disease, the development of diagnostic techniques, and a favourable regulatory environment for innovative first-in-class curative drugs, all of which are expected to expand the market's size and allow drug manufacturers to penetrate deeper into the market.
  • North America region had a major share in terms of volume as well as value in the global Treatment-Resistant Depression (TRD) Treatment market in 2021 and is projected to continue its dominance over the forecast period.
  • Several new therapies are being developed to address the limitations of presently licenced drugs. AXS-05 (Axsome Therapeutics), Cariprazine (AbbVie), Esketamine DPI (Celon Pharma), AV-101 (VistaGen Therapeutics), REL 1017 (Relmada Therapeutics, Inc./Syneos Health), and MIJ821 (Novartis Pharmaceuticals) are a few examples.
  • Companies and academics are collaborating to examine problems and identify possibilities that may have an impact on treatment-resistant depression (TRD) research and development. Novel techniques to treating/improving medical conditions are the focus of the medicines in development. Treatment-resistant depression therapies are being developed by major players (TRD). The introduction of new medicines will have a substantial impact on the market for treatment-resistant depression (TRD).

Who are the Top 10 players/companies in the Treatment-Resistant Depression (TRD) Treatment market in term of value?

The key players in the global Treatment-Resistant Depression (TRD) Treatment market in terms of value include AstraZeneca, Pfizer, Inc., GlaxoSmithKline plc, Eli Lilly and Company, Bristol-Myers Squibb Company, Forest Laboratories, Janssen Pharmaceuticals, Inc., and others. These key players are concentrating on new product developments as well as technological innovation to enhance their production in Treatment-Resistant Depression (TRD) Treatment to gain competitive market share at a global level. For instance, in February 2022, The US Food and Drug Administration (FDA) has approved AbbVie's supplemental New Drug Application (sNDA) for cariprazine (VRAYLAR) for the adjunctive treatment of major depressive disorder (MDD) in patients who are taking antidepressants. On the other hand, in March 2019, the FDA has approved Jansen Pharmaceuticals, Inc.'s Spravato nasal spray, which is an oral antidepressant intended to treat depression in individuals who have tried different antidepressants but have not found them to be effective.

Who are the Top 10 Countries in the Treatment-Resistant Depression (TRD) Treatment Market?

In the global Treatment-Resistant Depression (TRD) Treatment market, the major countries are US, Canada, China, Japan, Australia, Germany, France, Italy, Spain, and UK. The largest market share is in United States. According to the Anxiety and Depression Association of America (AADA), anxiety disorders are the most frequent mental ailment in the United States, impacting 40 million persons aged 18 and over, or 19.1% of the population, each year. The rise in the prevalence of  TRD, the rise in elderly populations, the rise in chronic diseases, and other similar variables are positively driving market expansion. The prevalence of TRD is highest in the 40-60 age group in the United States. As a result, TRD is regarded as the most neglected public health concern, with a projected prevalence of 2% to 3% for Stage 1 TRD and Stage 2 TRD. The market is being driven by an increase in the length of depression, severity of symptoms, the number of Alzheimer's cases, diabetics, epilepsy, high blood pressure, high cholesterol, and other clinical illnesses that have a significant impact on the body's natural functioning. In addition, the industry is growing due to manufacturers' eagerness for creating new FDA-approved medicines. The esketamine nasal spray was recently approved by the US Food and Drug Administration (USFDA) for the treatment of treatment-resistant depression. Esketamine is a medication that is used as a general anaesthetic and for treatment-resistant depression. It is sold under the brand names Ketanest and others. Esketamine is administered through injection into a vein or nasal spray. Esketamine is a non-competitive N-methyl-D-aspartate receptor antagonist in general.

Which is the Key distribution channel segment in the Treatment-Resistant Depression (TRD) Treatment Market?

The market is divided into three segments based on distribution channels: hospital pharmacies, retail pharmacies, and online pharmacies. With increased patient visits and sales of prescription-based medications for treatment of depressive disorders, primarily MDD, the hospital pharmacy industry has the major share internationally. Increasing Medications Prescriptions in Hospitals to Support Market Growth. The growing patient inclination to purchase products from nearby pharmacies on a frequent basis is driving the expansion of the retail pharmacies industry. However, because of the increasing penetration of online pharmacies in emerging nations, the online pharmacy industry is predicted to grow at a profitable rate over the projection period.

What are the Major Driving Factors for Treatment-Resistant Depression (TRD) Treatment Market?

The rise in the prevalence of depression (TRD), the rise in elderly populations, the rise in chronic diseases, and other similar variables are positively driving market expansion. Furthermore, an increase in the duration of depression, intensity of symptoms, an increase in Alzheimer cases, epilepsy, diabetics, high blood pressure, high cholesterol, and other clinical illnesses that significantly impact the normal functioning of the body are driving market expansion. Furthermore, the manufacturers' interest in creating new pharmaceuticals through FDA approval is driving market expansion.

What are the Major Restraints for Treatment-Resistant Depression (TRD) Treatment Market?

In the absence of FDA approval for the treatment of TRD, a specific combination of antidepressant medication combined with several therapy causes hazardous drug interaction, adverse drug reaction, and other side effects. The rising cost of therapy may stifle market expansion during the forecast period. One of the major barriers to TRD treatment implementation in emerging and developing nations is a lack of sufficient healthcare infrastructure due to low healthcare investment. Only a few healthcare facilities in developing and developing countries are currently equipped to use it.

Which Region Dominated the World Treatment-Resistant Depression (TRD) Treatment Market?

In 2021, North America dominates the Treatment-Resistant Depression (TRD) Treatment market over the forecast period because of a surge in treatment-resistant depression cases, an increase in the number of diabetic patients, new pharmaceutical approvals, newer treatment choices, and more knowledge about the illness. Increases in the prevalence of depression (TRD), older populations, chronic diseases, and other factors are all driving the market's expansion. Furthermore, an increase in the duration of depression, the severity of symptoms, the number of Alzheimer's cases, epilepsy, diabetics, high blood pressure, high cholesterol, and other clinical disorders that have a substantial impact on the body's natural functioning are driving the market. Furthermore, the sector is expanding as a result of manufacturers' enthusiasm in developing new FDA-approved therapies. According to a report published by the Centers for Disease Control and Prevention in October 2021 titled "National and State Trends in Anxiety and Depression Severity Scores Among Adults according to statistics from the US Census Bureau Household Pulse Survey, the percentage of US individuals exhibiting symptoms of anxiety and depression disorders increased nationwide from August 2020 to February 2021 during the COVID-19 Pandemic — the United States, 2020–2021. From August to December 2020, the average anxiety severity score climbed by 13%. From August 2020 to February 2021, the percentage of adults experiencing recent anxiety or depression symptoms climbed from 36.4 % to 41.5 %.

Asia Pacific is expected to grow at significant rate owing to an increase in the number of geriatrics, an increase in healthcare awareness, and an increase in government initiatives in the healthcare sector, an increase in depression, and an increase in research activities. According to Statista, almost 2.1 million episodes of depression among older adults were documented in India in 2020. Furthermore, the figure is expected to climb to roughly 5 million cases of depression among elderly adults. As a result, the fast increasing incidences of depression among the global population are increasing demand for depression therapy, which is fuelling global market expansion.

Segmentation of Global Treatment-Resistant Depression (TRD) Treatment Market-

Global Treatment-Resistant Depression (TRD) Treatment Market – By Drug Class 

  • Selective serotonin reuptake inhibitors
  • Monoamine Oxidase Inhibitors
  • Tricyclic Antidepressant Inhibitors
  • Anti-N-methyl-d-aspartate receptor
  • Others

Global Treatment-Resistant Depression (TRD) Treatment Market – By Distribution Channel 

  • Hospital pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently asked questions about the global Treatment-Resistant Depression (TRD) Treatment industry 

The global Treatment-Resistant Depression (TRD) Treatment market is expected to be impacted significantly by COVID-19.

North America accounted for the highest share in the global Treatment-Resistant Depression (TRD) Treatment market in terms of value.

The market for Treatment-Resistant Depression (TRD) Treatment has grown primarily as a result of major market drivers such as rising cancer prevalence, increased adoption of personalised medicine to tailor patient treatment on an individual level, and significant external funding for R&D.

Selective serotonin reuptake inhibitors segment had a major share in 2021 with more than 40% of the market revenue share.

Hospital pharmacies segment had a major share in 2021 with more than 30% of the market revenue share.

Treatment-Resistant Depression (TRD) Treatment Market Scope

Report Attribute Details
Market Value in 2021 USD 1318.5 million
Market Value in 2028 USD 1620.77 million
CAGR 3.50%
Benchmarking Year 2021
Past data 2016 – 2021
Forecast period 2022 – 2028
Choose License Type
Trusted By
Godaddy
Published Date:  Jul 2022
Category:  Pharmaceuticals
Report ID:   58359
Report Format:   PDF
Pages:   200
Rating:    4.8 (65)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support